Will 14-3-3η Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment.

Doaa Shawky Alashkar,Radwa Mostafa Elkhouly,Amira Yousef Abd Elnaby,Doaa Waseem Nada,Rizgar Mageed

doi:10.1155/2022/1497748

Abstract

Results Serum14-3-3η levels were significantly higher in all RA patients than in controls (P < 0.001), its sensitivity was 86.7% and 88.3% in early and established RA patients with a significant difference with RF and ACCP at early disease, and the specificity was 96.7%. There was a significant reduction of 14-3-3η levels 6 months after treatment in the first group (p=0.004), and there was a significant positive correlation between serum 14-3-3η levels and parameters of disease activity and severity. Conclusion 14-3-3η could be a novel, potent, and efficacious diagnostic, and prognostic marker for RA with high sensitivity, that may become a new therapeutic target for RA.

Highlights

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects about 1.5% of the population. ere are multiple pathophysiological factors in its etiology and manifestations, and there is high heterogeneity among patients throughout the disease
Samples and biotin labeling antibodies are added into ELISA plate wells and washed out with PBS or TBS. en Avidin-peroxidase conjugates are added to ELISA wells in order; TMB substrate was used for coloring after the reactant is thoroughly washed out by PBS or TBS
Results e results of this study revealed a highly significant difference between 14-3-3η, rheumatoid factor (RF), and anticyclic citrullinated peptide (ACCP) regarding sensitivity for RA diagnosis at early disease onset (p < 0.001), but not in established disease. e sensitivity of 14-3-3η was 86.7% and 88.3% in early and established RA, respectively

Summary

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects about 1.5% of the population. ere are multiple pathophysiological factors in its etiology and manifestations, and there is high heterogeneity among patients throughout the disease. It is understood that the disease outcome and patient prognosis can be significantly improved by early identification of RA and prediction of the disease severity at diagnosis for the implementation of an effective treatment strategy [2]. Laboratory data of patients with arthralgia, such as levels of rheumatoid factor (RF) and anticyclic citrullinated peptide (ACCP), are not remarkable for RA. E sensitivity of RF testing is 60 to 86% for established RA and 57% for early RA, but the utility of RF testing is somewhat limited by its low specificity of 70 to 85% for established and early RA [4]. CCP testing has sensitivity similar to that of RF for established RA (64% to 88%) and early RA (59%) [6], but its Autoimmune Diseases specificity (90 to 99%) is higher for both established and early disease [7]

Methods

Findings

Discussion

Conclusion